AI Tool Unveiled to Combat Superbugs in Houston Study

Newly-designed AI platform identifies antimicrobial peptides effective against MRSA and other antibiotic-resistant bacteria

Apr. 17, 2026 at 7:22am

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray image of a bacterial cell wall, its intricate structure glowing with an ethereal light, conceptually illustrating the potential of new antimicrobial therapies to target and disrupt the inner workings of these microscopic pathogens.An X-ray view of a bacterial cell wall reveals the complex structures that new AI-powered antimicrobial therapies aim to disrupt.Galveston Today

Researchers at Houston Methodist have developed an AI-powered tool called CAMPER that can identify antimicrobial peptides - small proteins that are part of the body's natural immune system - which are effective in targeting antibiotic-resistant bacteria like methicillin-resistant Staphylococcus aureus (MRSA) in lab tests. The study, published in Nature Communications, details how CAMPER uses machine learning and biologically informed features to evaluate and rank candidate peptides based on their physical, chemical, and predicted performance properties.

Why it matters

Antibiotic-resistant bacteria represent a major global health threat, with an estimated 2.8 million infections and more than 35,000 deaths annually in the U.S. Addressing this challenge is critical, and antimicrobial peptides offer a promising approach to target difficult-to-treat bacteria while reducing the likelihood of resistance. However, designing these molecules with precision has traditionally been complex and time intensive, which the CAMPER platform aims to overcome.

The details

The CAMPER platform, designed by first authors Fadi Shehadeh and Biswajit Mishra and their collaborators, integrates machine learning with biologically informed features to evaluate and rank libraries of candidate peptides. Using this approach, the team identified a promising candidate, WP-CAMPER1, which showed potent activity against MRSA at low concentrations and revealed its potential for treating antibiotic-resistant infections.

  • The study was published in Nature Communications on April 17, 2026.

The players

Eleftherios Mylonakis, M.D., Ph.D.

Chair of the Houston Methodist Charles W. Duncan Jr. Department of Medicine and the lead author of the study.

Fadi Shehadeh

First author of the study and a collaborator on the CAMPER platform.

Biswajit Mishra

First author of the study and a collaborator on the CAMPER platform.

Houston Methodist

The academic medical center where the research was conducted.

Nature Communications

The scientific journal that published the study.

Got photos? Submit your photos here. ›

What they’re saying

“Antibiotic-resistant bacteria represent a major global health threat, with an estimated 2.8 million infections and more than 35,000 deaths annually in the U.S. Addressing this challenge is critical.”

— Eleftherios Mylonakis, Chair, Houston Methodist Charles W. Duncan Jr. Department of Medicine

“Antimicrobial peptides offer a promising approach to target difficult-to-treat bacteria while reducing the likelihood of resistance. However, designing these molecules with precision has traditionally been complex and time intensive. To overcome this, we developed an AI-powered platform that enables the identification and design of peptides most effective against MRSA and other pathogens.”

— Eleftherios Mylonakis, Chair, Houston Methodist Charles W. Duncan Jr. Department of Medicine

“Ultimately, our study reports and validates the CAMPER methodology, demonstrating its ability to generate peptides that shows effectiveness against difficult-to-treat and persistent infections. It represents an important step toward a scalable platform for developing therapeutics targeting complex pathogens.”

— Eleftherios Mylonakis, Chair, Houston Methodist Charles W. Duncan Jr. Department of Medicine

What’s next

The researchers plan to further develop and test the CAMPER platform to identify additional antimicrobial peptides that could be used to treat antibiotic-resistant infections.

The takeaway

The development of the CAMPER AI platform represents a significant advancement in the fight against antibiotic-resistant bacteria, providing a scalable and efficient method for identifying promising antimicrobial peptides that could lead to new treatments for complex and persistent infections.